Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16751977 | 0.84 | AKR1C3 (0.43) | MAPK1AKR1C3AKR1C2FFAR2PSEN1 | |
| SCHEMBL16751910 | 0.81 | ALDH1A1 (0.40) | ALDH1A1AKR1C3AKR1C2FFAR2PSEN1 | |
| SCHEMBL30008055 | 0.78 | MAPK1 (0.41) | MAPK1SMN1; SMN2FFAR2PSEN1PSEN2 | |
| SCHEMBL16751962 | 0.76 | HCAR2 (0.42) | MAPK1AKR1C3AKR1C2FFAR2 | |
| SCHEMBL16751892 | 0.76 | AKR1C3 (0.49) | ALDH1A1MAPK1AKR1C3AKR1C2P4HTM | |
| SCHEMBL8357926 | 0.74 | ESR1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12302670 | 0.73 | MEN1 (0.41) | ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1062369 | 0.72 | AKR1C3 (0.51) | AKR1C3AKR1C2 | |
| SCHEMBL16751967 | 0.72 | AKR1C3 (0.50) | AKR1C3AKR1C2FFAR2PSEN1PSEN2 | |
| SCHEMBL9807335 | 0.71 | ESR1 (0.41) | AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | claimed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | claimed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | claimed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | claimed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | claimed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | claimed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | claimed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | claimed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | claimed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | claimed |
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | disclosed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | disclosed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | disclosed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | disclosed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201582-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885MAPK1 2589/4885SMN1; SMN2 1852/4885 |
| US-20160297762-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885MAPK1 2589/4885SMN1; SMN2 1852/4885 |
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885MAPK1 2589/4885SMN1; SMN2 1852/4885 |
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885MAPK1 2589/4885SMN1; SMN2 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.